Summary
The prognosis for patients with diffuse pontine gliomas (DPG) remains poor. New aggressive innovative treatments are necessary to treat this disease. From 1984 to 1998, eight patients (4M/4F), median age 11 years, with DPG were treated with monthly osmotic blood–brain barrier disruption (BBBD) chemotherapy using intraarterial carboplatin or methotrexate and intravenous cytoxan and etoposide. Patients presented for a median duration of 6 weeks with increased intracranial pressure, long tract signs, diplopia, ataxia, and nausea/vomiting. DPG was demonstrated on magnetic resonance (MR) imaging in seven patients and on CT in one. Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma. Three tumors enhanced on MR imaging after contrast administration. Three patients had radiation therapy before BBBD chemotherapy and four afterwards. Two patients had chemotherapy (tamoxifen, topotecan) before BBBD chemotherapy and two afterwards. In general, patients were evaluated with MR imaging every 3 months to monitor for a response to treatment. The median number of chemotherapy cycles that were administered by BBBD was 10, mean 10. Three patients also received one, two, or three cycles of intraarterial chemotherapy without BBBD. One patient that was started on carboplatin was converted to methotrexate, and five that were started on the methotrexate protocol were later converted over to carboplatin. One patient received monthly methotrexate followed by 14 days of procarbazine and one patient started on methotrexate was switched to navelbine. MR imaging demonstrated two partial responses, five patients with stable disease, and one with disease progression. The median time to tumor progression was 15 months with the range from <1 to 40 months. The median survival from the time of diagnosis was 27 months, ranging from 7 to 80 months. The median survival time from the first BBBD or intraarterial treatment was 16.5 months, ranging from 5 to 69 months. One patient was lost to follow-up with an unknown date of death. Although the sample size is small, the TTP and survival times are longer than those previously reported in other DPG series. In addition, the ability to demonstrate stable disease or partial responses in DPG on MR imaging argues for the therapeutic benefit of BBBD chemotherapy. The enhanced delivery of chemotherapy afforded by osmotic BBBD supports the further examination of this treatment modality for patients with DPG.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jallo GI, Biser-Rohrbaugh A, Freed D Brainstem gliomas Childs Nerv Syst 20: 143–153, 2004
Albright AL, Packer RJ, Zimmerman R, Rorke LB, Boyett J, Hammond GD Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children’s Cancer Group Neurosurgery 33: 1026–1030, 1993
Macdonald DR, Cascino TL, Schold SC, Cairncross JG Response criteria for Phase III studies of supratentorial malignant glioma J Clin Oncol 8: 1277–1280, 1990
Doolittle ND, Miner M, Hall WA, Siegal T, Hanson EJ, Osztie E, McAllister L, Bubalo J, Kraemer D, Fortin D, Nixon R, Muldoon LL, Neuwelt EA Safety and efficacy of a multi-center study using intraarterial chemotherapy in conjunction with osmotic opening of the blood–brain barrier for the treatment of malignant brain tumors Cancer 88: 637–47, 2000
Doolittle ND, Muldoon LL, Brummett RE, Tyson RM, Lacy C, Bubalo JS, Kraemer DF, Heinrich MC, Henry JA, Neuwelt EA Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors Clin Cancer Res 7: 493–500, 2001
Farmer JP, Montes JL, Freeman CR, Meagher-Villemure K, Bond MC, O’Gorman AM Brainstem gliomas. A 10-year institutional review Pediatr Neurosurg 34: 206–214, 2001
Carrie C, Negrier S, Gomez F, Thiesse P, Mottolese C, Frappaz D, Bouffet E Diffuse medulla oblongata and pontine gliomas in childhood Bull Cancer 91: E167–183, 2004
Schild SE, Stafford SL, Brown PD, Wood CP, Scheithauer BW, Schomberg PJ, Wong WW, Shaw EG The results of radiotherapy for brainstem tumors J Neuro-oncol 40: 171–177, 1998
Freeman CR, Bourgouin PM, Sanford RA, Cohen ME, Friedman HS, Kun LE Long term survivors of childhood brain stem gliomas treated with hyperfractionated radiotherapy clinical characteristics and treatment related toxicities. The Pediatric Oncology Group Cancer 77: 555–562, 1996
Mandell LR, Kadota R, Freeman C, Douglass EC, Fontanesi J, Cohen ME, Kovnar E, Burger P, Sanford RA, Kepner J, Friedman H, Kun LE There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy Int J Radiat Oncol Biol Phys 43: 959–964, 1999
Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP A phase I study of topotecan as a radiosensitizers for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952 Neuro-oncol 5: 8–13, 2003
Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, Billett AL, Kieran M, Tarbell NJ A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma Int J Radiat Oncol Biol Phys 55: 1182–1185, 2003
Allen J, Siffert J, Donahue B, Nirenberg A, Jakacki R, Robertson P, DaRosso R, Thoron L, Rosovsky M, Pinto R A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas Cancer 86: 1064–1099, 1999
Walter AW, Gajjar A, Ochs JS, Langston JW, Sanford RA, Kun LE, Heideman R Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: A phase I/II study Med Pediatr Oncol 30: 28–33, 1998
Bouffet E, Raquin M, Doz F, Gentet J-C, Rodary C, Demeocq F, Chastagner P, Lutz P, Hartmann O, Kalifa C Radiotherapy followed by high dose busulfan and thiotepa. A prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas Cancer 88: 685–692, 2000
Dunkel IJ, O’Malley B, Finlay JL Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood? Pediatr Neurosurg 24: 263–266, 1996
Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, Dana BW, Neuwelt EA Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood–brain tumor barrier in the treatment of intracranial neoplasms Neurosurgery 37: 17–28, 1995
Neuwelt EA, Brummett RE, Doolittle ND, Muldoon LL, Kroll RA, Pagel MA, Dojan R, Church V, Remsen LG, Bubalo JS First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate J Pharmacol Exp Ther 286: 77–84, 1998
Acknowledgements
This work was supported by a Veteran’s Administration Merit Review Grant and by NIH grants NS33618, NS34608, and NS44687 from the National Institutes of Neurological Disorders and Stroke to Dr. Edward A.␣Neuwelt.
Dr. Neuwelt, Dr. Muldoon, Oregon Health & Science University, Portland Veterans Affairs Medical Center and the Department of Veterans Affairs have significant financial interests in Adherex Technology, Inc., a company that may have a commercial interest in the results of this research and technology. The potential conflict of interest has been reviewed and a management plan has been approved by the Oregon Health & Science University and the Portland Veterans Affairs Medical Center Conflict of Interest in Research Committees.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hall, W.A., Doolittle, N.D., Daman, M. et al. Osmotic blood–brain barrier disruption chemotherapy for diffuse pontine gliomas. J Neurooncol 77, 279–284 (2006). https://doi.org/10.1007/s11060-005-9038-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-005-9038-4